Logo

Jazz Reports First Patient Enrollment in P-IIb Clinical Trial of Suvecaltamide for the Treatment of Essential Tremor

Share this

Jazz Reports First Patient Enrollment in P-IIb Clinical Trial of Suvecaltamide for the Treatment of Essential Tremor

Shots:

  • The first patient has been enrolled in a P-IIb clinical trial to evaluate the safety and efficacy of suvecaltamide vs PBO in 400 adults aged 18 to 80yrs. with moderate to severe ET across 50+ trial sites in the US, UK, and the EU
  • The primary efficacy EPs of the trial is the change from baseline @12wks. on the TETRAS composite outcome score representing the components from the TETRAS-activities of daily living and TETRAS-performance subscale, and measures the functional impact due to tremor. The results are expected in H1’24
  • Suvecaltamide (JZP385) is a highly selective modulator of T-type calcium channels which is currently in development for the treatment of moderate to severe ET

Ref: PR Newswire | Image: Jazz 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions